Drug promiscuity: problems and promises.
Abstract
Therapeutic drugs exert their effect by binding to a specific target protein (receptor) and altering its activity. However, all drugs have undesirable side effects, which likely result from the drug binding to other protein targets. Drug promiscuity refers to the ability of small molecule compounds to bind with high affinity to multiple proteins. This drug property is responsible for the problems caused by their side effects. But drug promiscuity also presents a promise: if a drug targets numerous proteins, each interaction may contribute to its therapeutic efficacy. The ability to target multiple genes is especially promising for medicines that treat systemic diseases, including neurological disorders and cancers, which result from gene network problems. Here, I will review both aspects of drug promiscuity and illustrate a potential strategy to move this forward using a computer modeling approach.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- FWCI
- 0.40
- Field percentile
- top 49%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The structural basis of drugs targeting protein-protein interactions uncovered with the protein-ligand interaction profiler PLIP
Sarah Naomi Bolz, Philipp Schake, … Michael Schroeder·Expert Opinion on Drug DiscoveryPeer-reviewed·Sep 5, 2025
- Structural and Functional View of Polypharmacology
Aurelio A. Moya‐García, Tolulope Tosin Adeyelu, … Juan A. G. Ranea·Scientific ReportsPeer-reviewed·Aug 24, 2017
- Identification of disease treatment mechanisms through the multiscale interactome
Camilo Ruiz, Marinka Žitnik, Jure Leskovec·Nature CommunicationsPeer-reviewed·Mar 19, 2021
- Investigating side effect modules in the interactome and their use in drug adverse effect discovery
Emre Güney·Springer proceedings in complexityPeer-reviewed·Jan 1, 2017
- Understanding Substance Dependence: What Differentiates Addictive from Non-Addictive Drugs?
Hargobind Singh, Hongyi Zhou, Samuel Skolnick·bioRxiv·May 8, 2026
- OmniBind: Proteome-Wide Promiscuity Predictions for Early-Stage Drug Screening
Josef Hanke, Sebastian Pujalte Ojeda, … Michele Vendruscolo·bioRxiv·Mar 18, 2026